In patients with cervicogenic headache caused by muscle spasm, which is more effective and safer: orphenadrine or eperisone (Myonal)?

Eperisone (Myonal) is the safer and more effective choice for cervicogenic headache with muscle spasm

For cervicogenic headache caused by muscle spasm, eperisone (Myonal) 150 mg/day divided into three doses is recommended over orphenadrine because it provides effective muscle relaxation without central nervous system adverse effects, while orphenadrine lacks specific evidence for cervicogenic headache and carries significant anticholinergic and sedative risks. 1, 2, 3, 4

Evidence Supporting Eperisone for Muscle Spasm

• Eperisone demonstrates proven efficacy in acute musculoskeletal spasm through a dual mechanism: it inhibits pain reflex pathways in the spinal cord while providing vasodilator effects that improve blood supply to contracted muscles, addressing both the neurological and ischemic components of muscle spasm. 3, 4

• In randomized controlled trials, eperisone 150 mg/day (50 mg three times daily) produced significant improvement in muscle spasm parameters including finger-to-floor distance (improving from 150.66 cm to 41.75 cm versus placebo 138.51 cm to 101.60 cm, P<0.001), reduction in muscle tenderness, and decreased need for rescue medication (35.71% versus 73.45% with placebo). 3

• Eperisone's unique vasodilator action is particularly relevant for cervicogenic headache, as muscle contracture compresses small blood vessels causing local ischemia and release of nociceptive compounds—a mechanism directly applicable to cervical muscle spasm causing headache. 4

• When compared head-to-head with baclofen in spastic conditions, eperisone 300 mg/day demonstrated superior improvement in upper limb functionality (-7.8%, P<0.01 versus -6.3%, P=NS) and joint range of motion (-32.5%, P<0.01 versus -14.6%, P=NS), suggesting better efficacy for cervical region involvement. 5

Critical Safety Advantage of Eperisone

• The most clinically significant advantage of eperisone is the absence of CNS adverse effects such as drowsiness, sedation, and cognitive impairment that limit the use of traditional muscle relaxants including orphenadrine. 4

• In clinical trials, eperisone was discontinued due to adverse effects in only 4% of patients, with mild gastrointestinal symptoms (nausea, abdominal pain) being the most common side effects—a markedly better tolerability profile than orphenadrine. 3, 4

• Eperisone does not increase fall risk in older persons, a critical safety concern with traditional muscle relaxants including orphenadrine, cyclobenzaprine, and benzodiazepines. 1

Why Orphenadrine is Not Recommended

• Current guidelines explicitly state that muscle relaxants like orphenadrine do not actually relieve muscle spasm—their effects are nonspecific and not related to true muscle relaxation, despite their marketing name. 1

• The American Geriatrics Society guidelines recommend that if muscle spasm is suspected, clinicians should consider drugs with known effects on muscle spasm (e.g., benzodiazepines, baclofen) rather than traditional "muscle relaxants" like orphenadrine, cyclobenzaprine, or methocarbamol. 1

• Orphenadrine is essentially identical to amitriptyline in structure, carrying similar anticholinergic adverse effects (dry mouth, urinary retention, constipation, confusion) plus significant sedation—side effects that impair quality of life and increase fall risk. 1

• There is no specific evidence supporting orphenadrine for cervicogenic headache, whereas eperisone has demonstrated efficacy in acute musculoskeletal conditions with neck involvement. 2, 3, 4

Specific Treatment Algorithm for Cervicogenic Headache with Muscle Spasm

Step 1: Initiate eperisone 50 mg three times daily (total 150 mg/day) for 10-14 days 3, 4

• Assess response at day 3 and day 10-14
• Expected improvements: reduced spontaneous and provoked pain, decreased muscle tenderness, improved cervical range of motion
• If gastrointestinal side effects occur (nausea, abdominal pain), consider taking with food

Step 2: If inadequate response after 14 days, consider escalation to eperisone 300 mg/day (100 mg three times daily) 5

• This higher dose has demonstrated efficacy in more severe spastic conditions
• Continue to monitor for adverse effects, though CNS effects remain absent even at higher doses

Step 3: For refractory cases, consider interventional approaches 2, 6

• Botulinum toxin type A injections into cervical muscles (most safe and efficacious for refractory cervicogenic headache)
• Greater occipital nerve blocks with local anesthetic or corticosteroids
• Radiofrequency ablation of C1-C3 nerve structures for persistent cases

Critical Pitfalls to Avoid

• Do not prescribe orphenadrine or other traditional "muscle relaxants" under the mistaken belief they relieve muscle spasm—guidelines explicitly state their effects are nonspecific and not related to actual muscle relaxation. 1

• Avoid combining eperisone with other muscle relaxants or sedating medications during the initial trial period to accurately assess its efficacy and tolerability profile. 3, 4

• Do not continue ineffective therapy beyond 2-3 weeks—if eperisone at 300 mg/day does not provide significant benefit after adequate trial, transition to interventional approaches rather than adding multiple oral agents. 2, 6

• Monitor older patients carefully for any unexpected sedation or cognitive effects, though these are not characteristic of eperisone; if such effects occur, consider drug interactions or alternative diagnoses. 1, 4

Comparative Safety Profile

Parameter	Eperisone	Orphenadrine
CNS sedation	Absent [4]	Significant [1]
Fall risk	No increase [4]	Increased [1]
Anticholinergic effects	Minimal [3,4]	Significant [1]
True muscle relaxation	Yes (proven mechanism) [3,4]	No (nonspecific effects) [1]
Evidence for cervicogenic headache	Applicable (neck/back spasm) [3,4]	None [1]
Discontinuation rate	4% [3]	Higher (not specified) [1]

The evidence strongly favors eperisone over orphenadrine for both efficacy and safety in managing cervicogenic headache with muscle spasm, with the critical advantage of avoiding CNS adverse effects while providing genuine muscle relaxation through a validated mechanism of action. 1, 3, 4, 5